Aldevron adds AAV plasmid product offerings

By The Science Advisory Board staff writers

January 12, 2021 -- Aldevron has launched rep/cap plasmids to support adeno-associated virus (AAV) vector manufacturing.

Rep/cap plasmids are essential components of the AAV genome and are required for the production of recombinant AAV.

The research grade product, pALD-AAV6 is immediately available at the good manufacturing practice (GMP) source quality level, while pALD-AAV2 and pALD-AAV5 will be made available based on market demand. These products are designed to support preclinical activities through clinical development and commercial production, according to Aldevron.

"Along with offering catalog items, we have increased capacity and reduced lead times, providing us the ability to scale while meeting important client deadlines," Michelle Berg, president of Aldevron's GMP nucleic acids business unit.

Genprex expands gene therapy manufacturing
Genprex has expanded its program to manufacture tumor suppressor candidate 2 (TUSC2) with a new manufacturing agreement with partner Aldevron.

Copyright © 2021

Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter